Exchange: NYSEMkt·Updated 04:18 AM EST

PLX News

News
all
press releases
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business...
PR Newswire
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business...
PR Newswire
More News
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results PR Newswire CARMIEL, Israel, March...
PR Newswire
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business...
PR Newswire
The Committee for Medicinal Products for Human Use recommended approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients.
Stocktwits
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (Protalix or the Company) (NYSE...
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire
However, Protalix CEO said that the results of the review do not change the priority of the company to reduce treatment burden for patients with Fabry disease.
Stocktwits
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.
Stocktwits
Investing.com -- Pluxee NV (EPA:PLX) reported 12.1% organic growth in first-quarter operating revenue, beating market expectations, and sending its shares soaring 11% in European trading Wednesday.
investing.com

Advertisement|Remove ads.